Abstract
In this open-label pilot study, the authors evaluated the effect of memantine on the distribution of brain glucose metabolism in four Huntington's disease (HD) patients as determined by serial 18-fluoro-deoxyglucose [F(18)]FDG-PET scans over a period of 3-4 months (90-129 days, with one patient choosing to continue treatment over the 18-month follow-up period). The treatment regimen was well tolerated. No significant differences on neuropsychological parameters before and after treatment were detected; but the patient who continued treatment did not deteriorate at 18 months' reevaluation, whereas the three patients who had stopped treatment after 3 to 4 months had minor progression in all cognitive domains on re-evaluation 12 months after the end of treatment.
| Original language | English |
|---|---|
| Journal | The Journal of Neuropsychiatry and Clinical Neurosciences |
| Volume | 23 |
| Issue number | 2 |
| Pages (from-to) | 206-10 |
| Number of pages | 5 |
| DOIs | |
| Publication status | Published - 2011 |
Keywords
- Adult
- Brain
- Disease Progression
- Excitatory Amino Acid Antagonists
- Glucose
- Humans
- Huntington Disease
- Memantine
- Middle Aged
- Neuropsychological Tests
- Pilot Projects
- Receptors, N-Methyl-D-Aspartate